JAK inhibitors represent a tremendous therapeutic advancement in the MPN field, having brought unprecedented benefits to patients, particularly those with MF, and their success has underscored the central role that overactive JAK-STAT signaling plays in these diseases [1]. This evidence concerns the gene SOAT1 and myeloproliferative neoplasm.